Table 3.
MIP:ACA:CDDP triple combination treatment on various human cancer cell lines
| Cancer type | Cell line | MIP:ACA:CDDP (25:25:25)
|
MIP:ACA:CDDP (10:10:10)
|
||||
|---|---|---|---|---|---|---|---|
| IC50a | CI | Relation | IC50a | CI | Relation | ||
| Breast | MCF-7 | 0.6±0.4 | 0.92 | AD | 0.27±0.3 | 0.41 | S |
| MDA-MB-231 | 1.8±0.1 | 1.0 | AD | 1.3±0.2 | 0.44 | S | |
| Cervical | CaSki | 1.2±0.1 | 1.1 | AD | 2.5±0.5 | 0.82 | AD |
| SiHa | 2.0±0.7 | 1.6 | AT | 3.2+0.2 | 0.4 | S | |
| HeLa S3 | 1.5±0.1 | 1.3 | AT | 0.5+0.3 | 0.7 | S | |
| Lung | A549 | 1.4±0.1 | 1.7 | AT | n/a | n/a | n/a |
| SK-LU-1 | 1.4±0.1 | 1.9 | AT | n/a | n/a | n/a | |
| Prostate | PC-3 | 4±0.13 | 1.7 | AT | 2.9±0.1 | 0.48 | S |
| DU-145 | 1.4±0.1 | 1.5 | AT | 12+1.6 | 1.1 | AD | |
| Liver | HepG2 | 0.3±0.3 | 1.2 | AD | 0.2+0.1 | 0.6 | S |
| Bladder | EJ-28 | 3.5±0.4 | 1.0 | AD | n/a | n/a | n/a |
| RT-112 | 2.0±0.2 | 1.3 | AT | 3.5+0.6 | 0.6 | S | |
| Oral | ORL-48 | 4.4±0.1 | 1.1 | AD | 0.5+1 | 0.4 | S |
| ORL-115 | 3.0±0.1 | 1.4 | AT | n/a | n/a | n/a | |
| Normal cell | MCF-10A | n/a | n/a | n/a | n/a | n/a | n/a |
Note:
a
IC50 (μL/[1.0×106 MIP cells/mL]) shows amount of MIP required to achieve 50% cell killing at constant ACA or CDDP.
Abbreviations: ACA, acetoxychavicol acetate; AD, additive; AT, antagonistic; CDDP, cisplatin; CI, combination index; MIP, Mycobacterium indicus pranii; n/a, not applicable; S, synergistic.